• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GE Healthcare’s new Vizamyl Alzheimer’s disease detector comes to the U.S.

GE Healthcare’s new Vizamyl Alzheimer’s disease detector comes to the U.S.

April 29, 2014 By Arezu Sarvestani

GE Healthcare launches Vizamyl Alzheimer's disease detector

GE Healthcare’s (NYSE:GE) newly FDA-approved Vizamyl imaging agent is about to make its initial appearance in 7 U.S. markets, where doctors can use it to help diagnose patients with Alzheimer’s disease and dementia.

Vizamyl is only the 2nd FDA-approved drug for detecting the abnormal buildup of beta amyloid proteins in the brain, a key indicator of Alzheimer’s disease. Vizamyl is also the 1st drug approved for visual interpretation of color images, rather than in black and white.

GE plans late in the 2nd quarter to offer the agent to imaging centers in: East Rutherford, N.J; Woburn, Mass.; Beltsville, Md.; East Lansing, Mich.; Dallas, Texas; Phoenix, Ariz.; and Colton, Calif.

"The commercial availability of Vizamyl and rollout of the electronic training program represent our commitment to helping physicians deliver more accurate and timely assessments of patients with cognitive disorders," GE Healthcare Life Sciences PET Neurology director Ben Newton said in prepared remarks. ""The ability to detect or exclude the presence of beta amyloid plaques in the brain may help physicians make more accurate assessments of patients with suspected cognitive disorders, including AD."

GE in October won the FDA nod to market the Vizamyl agent in detection of Alzheimer’s disease and dementia, with approval based on a pair of clinical trials with 761 total patient participants. Those studies demonstrated that the "Vizamyl correctly detects beta amyloid in the brain," and that the scans produced with Vizamyl are reproducible and translatable by trained readers, according to the FDA notice.

The only other imaging agency with FDA approval for the detection of beta amyloids in diagnosis of Alzheimer’s is Eli Lilly’s (NYSE:LLY) Amyvid, which won FDA approval last year and has since struggled to get wider reimbursement from the Centers for Medicare & Medicaid Services.

Filed Under: Neurological, News Well Tagged With: Alzheimer's disease, GE Healthcare

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy